Rising interest rates have raised concerns about the ability of biotechs to access capital. Contrary to popular perception, though, the sector is actually quite “healthy”, says portfolio manager Dr Bianca Ogden. Dedicated health funds are stepping in to provide support, while biotechs are refocusing and streamlining their product range, and there has been a flurry of mergers and acquisitions – as the sector prepares for the next chapter of growth.
From the journal
Small grounds, world-class players
Some small economies host brilliant businesses. Here's some of the best
TSMC – indispensable to the AI revolution?
TSMC is pivotal to the AI revolution. Here’s how we invest in it.
Video – The lure of large numbers
The Platinum team look at some high-quality companies growing their businesses in huge markets
Fear of Running Out
Uranium buyers are worried about supply. That could be good news for investors.
Subscribe to Platinum
Receive our expert investment insights and market updates.
Journal Articles
Read market leading insights.
Market Updates
Get market updates from our analysts
Quarterly Reports
Receive quarterly investment reports